Stocks-BIIB-Biogen Inc

BIIB Biogen Inc

283.63 -3.89 (-1.35%)
Vertraagde koersen door NASDAQ, in USD Markt gesloten
Beleg
Stocks-BIIB-Biogen Inc
BIIB Biogen Inc
Beleg
-3.02% Afgelopen week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Marktkapitalisatie
40.84B
Dagbereik
282.03
-
290.21
52W Bereik
186.98
-
310.52
Volume (3M)
1.2M
Prijs-Winstverhouding
14.45
Inkomsten
9.65B

Biogen Inc Laatste nieuws

Bekijk alle
How To Trade Biogen Inc. Common Stock BIIBHow To Trade Biogen Inc. Common Stock BIIBStock Traders Dailyongeveer 12 uur geledenDepression treatments havenโ€™t changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.Depression treatments havenโ€™t changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.Business Insider Nederlands3 dagen geledenBiogen and C4 Therapeutics divulge new IRAK-4-targeting PROTACsBiogen and C4 Therapeutics divulge new IRAK-4-targeting PROTACsBioWorld4 dagen geleden
Vastgezet bericht
eToro Team
eToro
13 dagen geleden
๐ŸŽ‰ Hereโ€™s a little preview introducing 16 YEARS of INVESTING on eToro ๐Ÿ˜๐Ÿค‘ With love, - The eToro Team youtu.be/UFYvpJxh2qA Vertalen
How can eToro celebrate 16 years of Investing?
youtu.be
Celebrating 16 years of investing together ๐Ÿ’š #etoro16
Like ReactieDelen
Toon meer opmerkingen2 van 66
1 reactie
null
.
Top Discussies
DeepNews
eToro
6 dagen geleden
$BIIB (Biogen Inc) Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Investors will be hoping for strength from Biogen Inc. as it approaches its next earnings release, which is expected to be February 15, 2023. The company is expected to report EPS of $3.48, up 2.65% from the... Meer weergeven Vertalen
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
finance.yahoo.com
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Like ReactieDelen
DeepNews
eToro
8 dagen geleden
$BIIB (Biogen Inc) Analysts Update Their Estimates For Biogen Inc. Biogen Inc. (NASDAQ:BIIB) concluded the trading at $290.08 on Friday, January 27 with a fall of -0.63% from its closing price on previous day. stocksregister.com/2023/01/28/analysts-update-their-estimates-for-biogen-inc/ Vertalen
Analysts Update Their Estimates For Biogen Inc.
stocksregister.com
Biogen Inc. (NASDAQ:BIIB) concluded the trading at $290.08 on Friday, January 27 with a fall of -0.63% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $291.92 and 5Y monthly beta was reading 0.17 with its price kept floating in the ran
Like ReactieDelen
DeepNews
eToro
9 dagen geleden
$BIIB (Biogen Inc) Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review. finance.yahoo.com/news/biogen-biib-eisais-lecanemab-secures-145702597.html Vertalen
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
finance.yahoo.com
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Like ReactieDelen
Esquis_AS
Frankrijk
19 dagen geleden
A @dividends_Income Elite Popular Investor shared portfolio: www.etoro.com/people/dividends_income .โญ ๐’๐ˆ๐Œ๐๐‹๐˜ ๐’๐€๐…๐„ ๐ƒ๐ˆ๐•๐ˆ๐ƒ๐„๐๐ƒ๐’ ๐ˆ๐๐‚๐Ž๐Œ๐„ โญ .๐ŸŽฏ Looser Mindset vs Winner Mindsed ๐ŸŽฏ .๐—ฃ๐—ผ๐—ฟ๐˜๐—ณ๐—ผ๐—น๐—ถ๐—ผ >๐—œ๐—ป๐˜ƒ๐—ฒ๐˜€๐˜๐—ผ๐—ฟ ๐—ฅ๐—ฒ๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ Hi team! I gonna try through this post to... Meer weergeven Vertalen
Like ReactieDelen
null
.
DeepNews
eToro
20 dagen geleden
$BIIB (Biogen Inc) Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan Biogen Inc. BIIB and partner Eisai announced that the latter submitted a marketing authorization application seeking approval for their anti-amyloid beta protofibril antibody candidate, lecanemab to treat mild cognitive... Meer weergeven Vertalen
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
www.msn.com
Biogen Inc. BIIB and partner Eisai announced that the latter submitted a marketing authorization application seeking approval for their anti-amyloid beta protofibril antibody candidate, lecanemab to treat mild cognitive impairment due to Alzheimerโ€™s disease (AD) mild AD dementia (collectively known as early AD) with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency. The filing in Japan was...
Like ReactieDelen

Over Biogen Inc

Biogen Inc. ontdekt, ontwikkelt, produceert en levert internationaal therapieรซn voor de behandeling van neurologische en neurodegeneratieve ziekten. Dit bedrijf werd opgericht in 1978 en heeft zijn hoofdkantoor in Cambridge, Massachusetts. De aandelen van Biogen Inc. worden verhandeld op de NASDAQ met het aandelensymbool BIIB. Breid uw eToro-portfolio uit met aandelen van deze onderneming.
9.6K
Medewerkers
Cambridge, Massachusetts, US
HQ
1978
Opgericht
Christopher A. Viehbacher, CPA
CEO
Show More
Med-techNASDAQ

Aankomende winstrapporten

15
FEB
RAPPORTEN
De publicatie van de cijfers van Biogen IncQ42022 wordt vandaag verwacht voordat de markt opent

ESG: Een nieuwe bron van inzicht

Wat is een ESG-score?
Dit cijfer is een maatstaf voor de blootstelling van een bedrijf aan risico's op het gebied van milieu, maatschappij en bestuur. Factoren die van invloed zijn, zijn onder meer energie-efficiรซntie, veiligheid en sociaal beleid. Meer informatie
Aangedreven door ESG Book
Krijg inzicht in de duurzaamheid van een bedrijf met behulp van ESG-scores (environmental, social en governance).
0
100
54
Medium
Sector 
Gem. 45 
62
Omgeving
62
Sociaal
42
Bestuur

Mensen kochten ook